Key Highlights
- HIMS stock climbs 7% during premarket hours Thursday, adding to Wednesday’s 10% advance and marking a fourth consecutive session of positive momentum
- The weekly surge of 64% represents the company’s strongest seven-day period in its trading history
- A partnership agreement with Novo Nordisk enables HIMS to distribute FDA-approved Ozempic and Wegovy through its digital platform, catalyzing the rally
- Barclays increased its price target to $29 from $25 while maintaining an “overweight” stance; Bank of America moved from “underperform” to “neutral” with a $23 target
- Fourth quarter EPS reached $0.08, significantly exceeding the $0.02 projection, while revenue of $617.8M came marginally below the $619.5M forecast
Hims & Hers Health (HIMS) experienced an extraordinary week of trading. Premarket activity Thursday showed approximately 7% gains, building on Wednesday’s 10% climb. The stock has posted positive returns for four trading sessions in a row.
Hims & Hers Health, Inc., HIMS
By Wednesday’s closing bell, HIMS had accumulated a 64% weekly advance. This performance marks the highest seven-day gain in company history.
Monday brought the initial catalyst when Novo Nordisk announced plans to offer its weight-loss medications via the Hims & Hers digital ecosystem. This arrangement resolved lingering legal uncertainties that had pressured the stock.
The partnership allows Hims & Hers to provide FDA-approved Ozempic and Wegovy directly to consumers using its telehealth infrastructure. Industry analysts have identified this as a meaningful contributor to both top-line growth and profitability metrics.
HIMS reached $26.17 during Wednesday’s midday session, gaining $2.70 from the prior close, while trading volume reached 51.6 million shares—substantially higher than the typical 33.3 million average.
Wall Street Raises Targets
The Novo Nordisk announcement prompted multiple brokerage firms to revise their outlooks. Barclays elevated its price objective to $29 from $25, maintaining an “overweight” recommendation. This target suggests approximately 10.8% appreciation potential from recent levels.
Bank of America shifted its stance to “neutral” from “underperform” and raised its target to $23 from $12.50. Deutsche Bank adjusted its projection upward to $28 from $25, keeping a “hold” rating in place.
MarketBeat data shows an aggregate consensus rating of “Hold” with an average price target of $30.75. The analyst community breakdown includes three Buy ratings, thirteen Hold recommendations, and one Sell rating.
Options markets displayed exceptional activity, with approximately 322,000 call contracts changing hands—indicating robust bullish sentiment that can intensify upward price movement.
Fourth Quarter Results and Capital Return
HIMS released Q4 financial results on February 23. Earnings per share totaled $0.08, substantially surpassing the $0.02 analyst projection. Revenue reached $617.8 million, slightly trailing the $619.5 million consensus estimate.
Revenue still expanded 28.4% compared to the year-earlier period. The company generated return on equity of 22.48% alongside a net margin of 5.47%.
The board authorized a $250 million share repurchase program, representing roughly 3% of shares outstanding. Buyback announcements generally indicate management’s view that current valuation presents attractive value.
Analysts project full-year EPS of $0.29 for the ongoing fiscal period.
The 52-week trading range spans $13.74 to $70.43. Wednesday’s closing price positioned the stock above its 50-day moving average of $24.31, though below the 200-day moving average of $37.75.
Despite recent momentum, short interest continues to draw attention. Market observers have noted potential squeeze dynamics that could drive volatility—upward moves fueled by short covering may experience rapid reversals once speculative positioning unwinds.
Institutional ownership stands at 63.52% of total shares. Company insiders control 17.71%, with insider transactions showing 80,463 shares sold during the most recent quarter.
